AZD2171
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukaemia
Conditions
Leukaemia, Myelocytic, Acute
Trial Timeline
Apr 1, 2004 → —
NCT ID
NCT00502385About AZD2171
AZD2171 is a phase 1 stage product being developed by AstraZeneca for Leukaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00502385. Target conditions include Leukaemia, Myelocytic, Acute.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00621725 | Phase 1 | Completed |
| NCT00385203 | Phase 2 | Completed |
| NCT00243347 | Phase 1 | Completed |
| NCT00503412 | Phase 1 | Completed |
| NCT00264004 | Phase 2 | Completed |
| NCT00503477 | Phase 1 | Completed |
| NCT00502385 | Phase 1 | Completed |
| NCT00502164 | Phase 1 | Completed |
| NCT00501605 | Phase 1 | Completed |
Competing Products
20 competing products in Leukaemia